Teva Pharmaceutical Industries Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard D. Francis
- Full Time Employees
- 32,008
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 124 Dvora Hanevi'a Street Tel Aviv TA Israel 6944020
- IPO Date
- Feb 16, 1982
- CIK
- 0000818686
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited, an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Petah Tikva, Israel, develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products worldwide across more than 60 countries with manufacturing facilities in Israel, North America, Europe, Australia and South America; core generic offerings span various dosage forms including tablets, capsules, ointments, creams, liquids, injectables and inhalants for therapeutic areas such as pain management, cardiovascular diseases, infectious diseases, central nervous system disorders, respiratory conditions, oncology and generics leadership in complex products; key innovative medicines include AUSTEDO (deutetrabenazine) for chorea in Huntington's disease and tardive dyskinesia, AJOVY (fremanezumab) for migraine prevention, UZEDY for schizophrenia, Copaxone for multiple sclerosis and a pipeline featuring olanzapine LAI, duvakitug for inflammatory bowel disease, DARI asthma inhaler, emrusolmin and TEV-56278 (anti-PD1-IL2 ATTENUKINE) for oncology. The company operates in segments including generics and biosimilars targeting healthcare providers, pharmacies and hospitals globally, with a focus on neuroscience, immunology, respiratory diseases and pain management customer bases. Teva advances its Pivot to Growth strategy, launched in 2023 and accelerated in 2025, to build a greater than $5 billion innovative medicines franchise by 2030 through robust late-stage pipeline execution, 25 to 27 biosimilar launches by 2027 including eculizumab-aagh with Samsung Bioepis and PONLIMSI/DEGEVMA denosumab biosimilars approved in Europe; recent strategic partnerships encompass a June 2025 collaboration with Fosun Pharma for TEV-56278 development in Asia, a prior alliance with Sanofi for TEV-574 anti-TL1A in inflammatory bowel disease, and the November 2025 launch of Teva Rise open innovation platform for AI, digital health and manufacturing advancements; ongoing efforts include divestiture of its API business TAPI announced in 2024, eleven consecutive quarters of revenue growth as of Q3 2025 driven by 33% innovative portfolio increase in local currency, reaffirmed 2027 targets of 30% operating profit margin, over $2.7 billion free cash flow and $2.5 billion Estero revenues with peak sales exceeding $3 billion, alongside credit upgrades reflecting debt reduction and operational enhancements.
Humana agrees not to reference Teva's Israel ties at US drug trial
Cetera Investment Advisers Acquires 26,789 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Teva seeks to keep Israel ties from jury, cites Gaza war
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Teva's Re-Rating Still Has Room To Run
Why Teva Pharmaceutical Stock Surged This Week
Teva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LP
Axiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.